Fecal Microbiota Transplantation for Recurrent Clostridioides difficile infection: The COVID-19 Era

Sahil Khanna; Darrell Pardi

doi:10.14309/ajg.0000000000000689

Fecal Microbiota Transplantation for Recurrent Clostridioides difficile infection: The COVID-19 Era

Sahil Khanna, Darrell Pardi

Gastroenterology and Hepatology

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Original language	English (US)
Pages (from-to)	971-974
Number of pages	4
Journal	American Journal of Gastroenterology
Volume	115
Issue number	7
DOIs	https://doi.org/10.14309/ajg.0000000000000689
State	Published - Jul 1 2020

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.14309/ajg.0000000000000689

Cite this

@article{48689426567643d68cb6193accac4125,

title = "Fecal Microbiota Transplantation for Recurrent Clostridioides difficile infection: The COVID-19 Era",

author = "Sahil Khanna and Darrell Pardi",

note = "Funding Information: Guarantor of the article: Sahil Khanna, MBBS, MS. Specific author contributions: S.K. wrote the manuscript and D.S.P. reviewed the manuscript. Financial support: None to report. Potential competing interests: S.K.: research grants from Rebiotix, Inc. (A Ferring company), consulting fees from Shire Plc, Premier Inc., Facile therapeutics, ProbioTech Inc., outside of the submitted work. D.S.P.: research grants from Vedanta, Seres therapeutics, consulting fees from Assembly Biosciences, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Merck & Co, Inc.; C3J Therapeutics, Inc.; Nestl{\'e}; and Salix Pharmaceuticals, outside of the submitted work.",

year = "2020",

month = jul,

day = "1",

doi = "10.14309/ajg.0000000000000689",

language = "English (US)",

volume = "115",

pages = "971--974",

journal = "American Journal of Gastroenterology",

issn = "0002-9270",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Fecal Microbiota Transplantation for Recurrent Clostridioides difficile infection

T2 - The COVID-19 Era

AU - Khanna, Sahil

AU - Pardi, Darrell

N1 - Funding Information: Guarantor of the article: Sahil Khanna, MBBS, MS. Specific author contributions: S.K. wrote the manuscript and D.S.P. reviewed the manuscript. Financial support: None to report. Potential competing interests: S.K.: research grants from Rebiotix, Inc. (A Ferring company), consulting fees from Shire Plc, Premier Inc., Facile therapeutics, ProbioTech Inc., outside of the submitted work. D.S.P.: research grants from Vedanta, Seres therapeutics, consulting fees from Assembly Biosciences, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Merck & Co, Inc.; C3J Therapeutics, Inc.; Nestlé; and Salix Pharmaceuticals, outside of the submitted work.

PY - 2020/7/1

Y1 - 2020/7/1

UR - http://www.scopus.com/inward/record.url?scp=85087471021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087471021&partnerID=8YFLogxK

U2 - 10.14309/ajg.0000000000000689

DO - 10.14309/ajg.0000000000000689

M3 - Article

C2 - 32618640

AN - SCOPUS:85087471021

SN - 0002-9270

VL - 115

SP - 971

EP - 974

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

IS - 7

ER -

Fecal Microbiota Transplantation for Recurrent Clostridioides difficile infection: The COVID-19 Era

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this